p53-Mediated Radiosensitization of <sup>177</sup>Lu-DOTATATE in Neuroblastoma Tumor Spheroids
p53 is involved in DNA damage response and is an exciting target for radiosensitization in cancer. Targeted radionuclide therapy against somatostatin receptors with <sup>177</sup>Lu-DOTATATE is currently being explored as a treatment for neuroblastoma. The aim of this study was to invest...
Guardado en:
Autores principales: | Sara Lundsten, Hanna Berglund, Preeti Jha, Cecilia Krona, Mehran Hariri, Sven Nelander, David P. Lane, Marika Nestor |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4d7ad4c2ba884c0ea627c2e375ac1c7a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry Rationale
por: Andreas Hallqvist, et al.
Publicado: (2021) -
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Peter Frøhlich Staanum, et al.
Publicado: (2021) -
Brachytherapy Approach Using <sup>177</sup>Lu Conjugated Gold Nanostars and Evaluation of Biodistribution, Tumor Retention, Dosimetry and Therapeutic Efficacy in Head and Neck Tumor Model
por: Min-Ying Lin, et al.
Publicado: (2021) -
Separation of <sup>44</sup>Sc from <sup>44</sup>Ti in the Context of A Generator System for Radiopharmaceutical Purposes with the Example of [<sup>44</sup>Sc]Sc-PSMA-617 and [<sup>44</sup>Sc]Sc-PSMA-I&T Synthesis
por: Anton A. Larenkov, et al.
Publicado: (2021) -
Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
por: Matthew Glover, et al.
Publicado: (2021)